PT  - JOURNAL ARTICLE
AU  - Wenjuan Zhang
AU  - Brian D Davis
AU  - Stephanie S Chen
AU  - Jorge M Sincuir Martinez
AU  - Jasmine T Plummer
AU  - Eric Vail
TI  - Emergence of a novel SARS-CoV-2 strain in Southern California, USA
AID  - 10.1101/2021.01.18.21249786
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.18.21249786
4099  - http://medrxiv.org/content/early/2021/01/20/2021.01.18.21249786.short
4100  - http://medrxiv.org/content/early/2021/01/20/2021.01.18.21249786.full
AB  - Since October 2020, novel strains of SARS-CoV-2 including B.1.1.7, have been identified to be of global significance from an infection and surveillance perspective. While this strain (B.1.1.7) may play an important role in increased COVID rates in the UK, there are still no reported strains to account for the spike of cases in Los Angeles (LA) and California as a whole, which currently has some of the highest absolute and per-capita COVID transmission rates in the country. From the early days of the pandemic when LA only had a single viral genome uploaded onto GISAID we have been at the forefront of generating and analyzing the SARS-CoV-2 sequencing data from the LA region. We report a novel strain emerging in Southern California. Most current cases in the catchment population in LA fall into two distinct subclades: 1) 20G (24% of total) is the predominant subclade currently in the United States 2) a relatively novel strain in clade 20C, CAL.20C strain (∼36% of total) is defined by five concurrent mutations. After an analysis of all of the publicly available data and a comparison to our recent sequences, we see a dramatic growth in the relative percentage of the CAL.20C strain beginning in November of 2020. The predominance of this strain coincides with the increased positivity rate seen in this region. Unlike 20G, this novel strain CAL.20C is defined by multiple mutations in the S protein, a characteristic it shares with both the UK and South African strains, both of which are of significant clinical and scientific interestCompeting Interest StatementThe authors have declared no competing interest.Funding StatementInternal funding from the Department of Biomedical Sciences, Cedars Sinai Medical Center was awarded for the execution and completion of this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Regulatory review was completed by the CSMC Office of Research Compliance and Quality Improvement (IRB # STUDY629).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data has been deposited to GISAID